Could an existing arthritis treatment help people with EGPA, an inflammatory disease that often targets blood vessels?

Chief Investigator

Dr Paul Russo B.Med.Sci (Hons), MBBS, FRACP

Dr Paul Russo is a Rheumatologist, Clinical Immunologist and Allergist from South Australia.

Award and Funder

Arthritis Australia National Research Program Private Practice Grant (2025)

Funded by Australian Rheumatology Association Research Fund is a grant for a lead investigator to conduct a research program in private practice.

Plain Language Summary

What JAK inhibitors in Eosinophilic Granulomatosis with Polyangiitis (EGPA): an international case series

This study explored whether JAK inhibitors might reduce patients’ reliance on long-term steroids, starting with one Australian patient in Dr Russo’s clinic and later extending across the world. Read the full summary in plain language to find out more about this study.

An important part of our National Research Program is sharing what we learn, so that the knowledge gained through research reaches the people who can use it — clinicians, patients and the wider community. We congratulate Dr Russo, who has presented these findings at two conferences:

  • The 10th Meeting of the European EGPA Study Group on September 18, 2026 (Paris, France)
  • Australian Rheumatology Association SA/NT annual scientific meeting on November 7, 2026 (Adelaide, South Australia)

Dr Russo’s research has also been published by the Journal of Rheumatology (Canada) which you can read here.

Scroll to Top

Search